Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sonia Cerquozzi & Carolyn Owen. (2015) Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 13-22.
Read now
Read now
Michael Doubek & Michal Šmída. (2015) Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. Expert Review of Hematology 8:6, pages 743-764.
Read now
Read now
Jon E Arnason & Jennifer R Brown. (2015) Obinutuzumab: its use in the management of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 3:7, pages 843-853.
Read now
Read now
Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook Kohrt, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology 4:1.
Read now
Read now
Carolyn J Owen & Douglas A Stewart. (2014) Obinutuzumab for B-cell malignancies. Expert Opinion on Biological Therapy 14:8, pages 1197-1205.
Read now
Read now
Divaya Bhutani & Ulka N Vaishampayan. (2013) Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opinion on Biological Therapy 13:2, pages 269-282.
Read now
Read now
Preetesh Jain & Susan O'Brien. (2013) Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 13:2, pages 169-182.
Read now
Read now
Articles from other publishers (22)
Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung & Man Fai Law. (2023) Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World Journal of Gastroenterology 29:33, pages 4942-4961.
Crossref
Crossref
Amir-Hassan Zarnani, Davood Jafari, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2021. Cancer Immunology. Cancer Immunology
273
312
.
Annarita Scialdone, Somayeh Khazaei, Muhammad Sharif Hasni, Andreas Lennartsson, Urban Gullberg & Kristina Drott. (2019) Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Experimental Hematology 79, pages 35-46.e1.
Crossref
Crossref
Sara Galimberti, Elisa Genuardi, Francesco Mazziotta, Lorenzo Iovino, Fortunato Morabito, Susanna Grassi, Elena Ciabatti, Francesca Guerrini & Mario Petrini. (2019) The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. Frontiers in Oncology 9.
Crossref
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
Chandrashekar Bohra, Lubomir Sokol & Samir Dalia. (2017) Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies. Cancer Control 24:4, pages 107327481772990.
Crossref
Crossref
Chiara Coluccio, Paola Begini, Alfredo Marzano, Adriano Pellicelli, Barbara Imperatrice, Giulia Anania, Gianfranco Delle Fave & Massimo Marignani. (2017) Hepatitis B in patients with hematological diseases: An update. World Journal of Hepatology 9:25, pages 1043.
Crossref
Crossref
Matthew Ku, Geoff Chong & Eliza A. Hawkes. (2017) Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. Blood Reviews 31:1, pages 23-35.
Crossref
Crossref
Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, Maddalena Mazzucchelli, Roberto Cairoli & Marco Montillo. (2016) Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data. Therapeutic Advances in Hematology 7:4, pages 222-230.
Crossref
Crossref
Man Fai Law, Rita Ho, Carmen K M Cheung, Lydia H P Tam, Karen Ma, Kent C Y So, Bonaventure Ip, Jacqueline So, Jennifer Lai, Joyce Ng & Tommy H C Tam. (2016) Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World Journal of Gastroenterology 22:28, pages 6484.
Crossref
Crossref
Joanie Del Bano, Patrick Chames, Daniel Baty & Brigitte Kerfelec. (2015) Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. Antibodies 5:1, pages 1.
Crossref
Crossref
Gang Deng, Xiaodong Zheng, Jing Zhou, Haiming Wei, Zhigang Tian & Rui Sun. (2015) Generation and Preclinical Characterization of an NKp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (NK) Cells against Leukemia. Journal of Biological Chemistry 290:37, pages 22474-22484.
Crossref
Crossref
Julia Steinbacher, Katrin Baltz-Ghahremanpour, Benjamin Joachim Schmiedel, Alexander Steinle, Gundram Jung, Ayline K?bler, Maya Caroline Andr?, Ludger Grosse-Hovest & Helmut Rainer Salih. (2015) An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. International Journal of Cancer 136:5, pages 1073-1084.
Crossref
Crossref
Jon E. Arnason & Jennifer R. Brown. (2015) Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions. Drugs 75:2, pages 143-155.
Crossref
Crossref
Amir-Hassan Zarnani, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2015. Cancer Immunology. Cancer Immunology
293
328
.
Stefanie Raab, Julia Steinbacher, Benjamin J. Schmiedel, Philaretos C. Kousis, Alexander Steinle, Gundram Jung, Ludger Grosse-Hovest & Helmut R. Salih. (2014) Fc-Optimized NKG2D–Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status. The Journal of Immunology 193:8, pages 4261-4272.
Crossref
Crossref
Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens M. Wendtner, Tatiana Chagorova, Javier de la Serna, Marie-Sarah Dilhuydy, Thomas Illmer, Stephen Opat, Carolyn J. Owen, Olga Samoylova, Karl-Anton Kreuzer, Stephan Stilgenbauer, Hartmut D?hner, Anton W. Langerak, Matthias Ritgen, Michael Kneba, Elina Asikanius, Kathryn Humphrey, Michael Wenger & Michael Hallek. (2014) Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine 370:12, pages 1101-1110.
Crossref
Crossref
H. Mabashi-Asazuma, C.-W. Kuo, K.-H. Khoo & D. L. Jarvis. (2013) A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells. Glycobiology 24:3, pages 325-340.
Crossref
Crossref
Jay J. Listinsky, Gene P. Siegal & Catherine M. Listinsky. (2013) Glycoengineering in cancer therapeutics. Anti-Cancer Drugs 24:3, pages 219-227.
Crossref
Crossref
Tadeusz Robak. (2013) Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology 9:1, pages 69-91.
Crossref
Crossref
Janice M. Reichert & Eugen Dhimolea. (2012) The future of antibodies as cancer drugs. Drug Discovery Today 17:17-18, pages 954-963.
Crossref
Crossref